Spots Global Cancer Trial Database for Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Official Title: An Open Label, Single/Multiple Dose Exploratory Clinical Study to Evaluate the Safety, Efficacy, and Cytokinetics of Autologous Humanized Anti-claudin18.2 Chimeric Antigen Receptor T Cell in Advanced Solid Tumor Subjects
Study ID: NCT03874897
Conditions
Study Description
Brief Summary: An open label, single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen receptor T cell in advanced solid tumor.
Detailed Description: This study is an open, single/multiple infusion, dose escalation/dose regimen finding study to assess the safety and pharmacokinetics of CAR-CLDN18.2 T cell therapy, and to obtain the preliminary efficacy results in subjects who have been diagnosed with advanced solid tumor with positive claudin 18.2 expression and failed to standard systemic treatment.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Department of GI Oncology, Peking University Cancer Hospital, Beijing, Beijing, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
The First Affiliated Hospital , Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Contact Details
Name: Lin Shen
Affiliation: Peking University Cancer Hospital & Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
